Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAVERIC: Maraviroc for HCV in HIV/HCV Co-infection
NCT02881762Phase 4Completed
- Sponsor
- University of Maryland, Baltimore
- Start
- Jun 2017
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of maraviroc in hepatitis C (HCV) (2 arms), sponsored by University of Maryland, Baltimore. Primary endpoint: Change in Hepatitis C Viral Load From Baseline to 4 Weeks of Maraviroc or No Maraviroc. Started Jun 2017; status: completed.
02
Drugs
maraviroc
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02881762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02881762.